logo
Plus   Neg
Share
Email

Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation

Eli Lilly and Co. and Incyte said that a Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib met the primary endpoint of at least 75% improvement of skin inflammation and key secondary endpoint.

The Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis. The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index at Week 16. The study was conducted in North America.

Atopic dermatitis, or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drugstore chain Walgreens and courier services provider Postmates said they have expanded on-demand delivery to more than 7,000 Walgreens stores nationwide. The companies expect the service will help capitalize on the rising need for home delivery amid the coronavirus pandemic. The expansion will enable consumers in cities across the country to get home delivery of health and wellness items. A growing number of retailers in the U.S. are furloughing their employees as the coronavirus pandemic has resulted in the temporary closure of retail stores nationwide. The store closures came as more people in the U.S. are forced to remain at home to help curtail the spread of COVID-19 by promoting social distancing. Ride-hailing giant Uber Technologies said it is offering 10 million free rides and food deliveries to healthcare workers, seniors, and people in need, amid the surging coronavirus or covid-19 crisis. Across the world, the company aims to work with more cities, food banks, hospitals and others to move what matters, such as getting first responders to work, and food to those who need it.
Follow RTT
>